ESMO 2017 | Pembrolizumab or EGFR tyrosine kinase inhibitors in NSCLC?
Silvia Novello, MD, PhD, from the San Luigi Hospital, Orbassano, Italy, discusses recent developments in immunotherapy and oncogene addiction at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. The KEYNOTE-021 study (NCT02039674) is a randomised trial investigating pembrolizumab in combination with immunotherapy or chemotherapy. This study found an advantage in immunotherapy combined with pembrolizumab. The FLAURA study (NCT02296125) investigated the use of an EGFR TKI in patients with non-small cell lung cancer, with promising results. Dr Novello does state that more information is needed in terms of oncogene addicted patients, as well as immunotherapy in elderly patients.
Get great new content delivered to your inboxSign up